Contact us

C. A. Olesens Gade 4, 3., 

9000 Aalborg, Denmark

Press

Want to write about us?
Or just looking for some ekstra information?

Find it here!

AW Technologies

Find us on
Linkedin logo.png

PROBLEM

Clinical challenges in ventilator-associated pneumonia prevention and treatment

Intensive Care Units spent enormous amounts of money each years to prevent and treat patients with ventilator-associated pneumonia!

Globally, many intensive care unit practitioners are frustrated by the complications and ventilator-associated Pneumonia infections that roughly 27% of the patients suffer during their Intensive Care Unit stay.

 

Ventilator-associated Pneumonia occurs because the bacterial secretion in the trachea is not efficiently removed and aspirates into the distal bronchi, thereby giving rise to pneumonia infection in the ventilated patient.

 

The number of ventilator-associated pneumonia incidences are high, with roughly 27% infection rate of all ventilated patients, and mortality rates between 25% and 50%.

Today, the best option for preventing ventilator-associated pneumonia is inserting a plastic catheter tube, into the endotracheal tube, and suctioning the secretion out from the trachea. This is the most common procedure available to remove secretion, as ventilated patients cannot themselves cough it up – as non-ventilated patients or healthy people can.

The 3 major challenges causing clinical challenges

1

High workload and consumable use

Ventilated patients' trachea is suctioned many times a day, each a long procedure to perform to prevent VAP and often are the consumables used replaced daily.

2

Inefficient solutions

The current solutions are inefficient as they cannot remove all secretion from the trachea

3

High pneumonia infection rate

The inefficient suctioning results in a high VAP infection rate, and an extended stay for the patient, resulting in extra costs for the ICU

AW Technologies